Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1992 May;89(5):1669–1673. doi: 10.1172/JCI115765

Platelet activating factor mediates interleukin-2-induced lung injury in the rat.

R Rabinovici 1, M D Sofronski 1, J F Renz 1, L M Hillegas 1, K M Esser 1, J Vernick 1, G Feuerstein 1
PMCID: PMC443045  PMID: 1314853

Abstract

Interleukin-2 was recently shown to cause acute lung injury characterized by microvascular permeability defect, interstitial edema, and leukosequestration. Similar responses can also be produced by platelet activating factor (PAF). Thus, the present study aimed to examine whether PAF plays a key role in the development of IL-2-induced lung injury in the anesthetized rat. Intravenous infusion (60 min) of recombinant human IL-2 at 10(5)-10(6) U/rat (n = 7-9) dose-dependently elevated lung water content (27 +/- 1%, P less than 0.01), myeloperoxidase activity (+84 +/- 23%, P less than 0.05), and serum thromboxane B2 (990 +/- 70%, P less than 0.01), but failed to alter blood pressure, hematocrit, serum tumor necrosis factor-alpha, and circulating leukocytes and platelets. Pretreatment (-30 min) with a potent and specific PAF antagonist, BN 50739 (10 mg/kg, intraperitoneally, n = 6) prevented the pulmonary edema (P less than 0.05) and thromboxane B2 production (P less than 0.01), and attenuated the elevation of lung myeloperoxidase activity (+18 +/- 16%, P less than 0.05) induced by IL-2. These data suggest that PAF is involved in the pathophysiological processes leading to IL-2-induced lung injury, and point to the potential therapeutic capacity of PAF antagonists in preventing pulmonary edema during IL-2 therapy.

Full text

PDF
1669

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson T. D., Hayes T. J., Gately M. K., Bontempo J. M., Stern L. L., Truitt G. A. Toxicity of human recombinant interleukin-2 in the mouse is mediated by interleukin-activated lymphocytes. Separation of efficacy and toxicity by selective lymphocyte subset depletion. Lab Invest. 1988 Nov;59(5):598–612. [PubMed] [Google Scholar]
  2. Atkins M. B., Gould J. A., Allegretta M., Li J. J., Dempsey R. A., Rudders R. A., Parkinson D. R., Reichlin S., Mier J. W. Phase I evaluation of recombinant interleukin-2 in patients with advanced malignant disease. J Clin Oncol. 1986 Sep;4(9):1380–1391. doi: 10.1200/JCO.1986.4.9.1380. [DOI] [PubMed] [Google Scholar]
  3. Beutler B., Cerami A. The common mediator of shock, cachexia, and tumor necrosis. Adv Immunol. 1988;42:213–231. doi: 10.1016/s0065-2776(08)60846-9. [DOI] [PubMed] [Google Scholar]
  4. Bradley P. P., Priebat D. A., Christensen R. D., Rothstein G. Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J Invest Dermatol. 1982 Mar;78(3):206–209. doi: 10.1111/1523-1747.ep12506462. [DOI] [PubMed] [Google Scholar]
  5. Braquet P., Touqui L., Shen T. Y., Vargaftig B. B. Perspectives in platelet-activating factor research. Pharmacol Rev. 1987 Jun;39(2):97–145. [PubMed] [Google Scholar]
  6. Bussolino F., Breviario F., Aglietta M., Sanavio F., Bosia A., Dejana E. Studies on the mechanism of interleukin 1 stimulation of platelet activating factor synthesis in human endothelial cells in culture. Biochim Biophys Acta. 1987 Jan 19;927(1):43–54. doi: 10.1016/0167-4889(87)90064-4. [DOI] [PubMed] [Google Scholar]
  7. Bussolino F., Foa R., Malavasi F., Ferrando M. L., Camussi G. Release of platelet-activating factor (PAF)-like material from human lymphoid cell lines. Exp Hematol. 1984 Oct;12(9):688–693. [PubMed] [Google Scholar]
  8. Camussi G., Aglietta M., Coda R., Bussolino F., Piacibello W., Tetta C. Release of platelet-activating factor (PAF) and histamine. II. The cellular origin of human PAF: monocytes, polymorphonuclear neutrophils and basophils. Immunology. 1981 Feb;42(2):191–199. [PMC free article] [PubMed] [Google Scholar]
  9. Dahinden C. A., Zingg J., Maly F. E., de Weck A. L. Leukotriene production in human neutrophils primed by recombinant human granulocyte/macrophage colony-stimulating factor and stimulated with the complement component C5A and FMLP as second signals. J Exp Med. 1988 Apr 1;167(4):1281–1295. doi: 10.1084/jem.167.4.1281. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Damle N. K., Doyle L. V., Bender J. R., Bradley E. C. Interleukin 2-activated human lymphocytes exhibit enhanced adhesion to normal vascular endothelial cells and cause their lysis. J Immunol. 1987 Mar 15;138(6):1779–1785. [PubMed] [Google Scholar]
  11. Damle N. K., Doyle L. V. IL-2-activated human killer lymphocytes but not their secreted products mediate increase in albumin flux across cultured endothelial monolayers. Implications for vascular leak syndrome. J Immunol. 1989 Apr 15;142(8):2660–2669. [PubMed] [Google Scholar]
  12. Dinarello C. A. Interleukin-1. Rev Infect Dis. 1984 Jan-Feb;6(1):51–95. doi: 10.1093/clinids/6.1.51. [DOI] [PubMed] [Google Scholar]
  13. Ettinghausen S. E., Rosenberg S. A. Immunotherapy of murine sarcomas using lymphokine activated killer cells: optimization of the schedule and route of administration of recombinant interleukin-2. Cancer Res. 1986 Jun;46(6):2784–2792. [PubMed] [Google Scholar]
  14. Ezra D., Laurindo F. R., Czaja J. F., Snyder F., Goldstein R. E., Feuerstein G. Cardiac and coronary consequences of intracoronary platelet activating factor infusion in the domestic pig. Prostaglandins. 1987 Jul;34(1):41–57. doi: 10.1016/0090-6980(87)90261-9. [DOI] [PubMed] [Google Scholar]
  15. Feuerstein G., Hallenbeck J. M., Vanatta B., Rabinovici R., Perera P. Y., Vogel S. N. Effect of gram-negative endotoxin on levels of serum corticosterone, TNF alpha, circulating blood cells, and the survival of rats. Circ Shock. 1990 Mar;30(3):265–278. [PubMed] [Google Scholar]
  16. Glauser F. L., DeBlois G. G., Bechard D. E., Merchant R. E., Grant A. J., Fowler A. A., Fairman R. P. Cardiopulmonary effects of recombinant interleukin-2 infusion in sheep. J Appl Physiol (1985) 1988 Mar;64(3):1030–1037. doi: 10.1152/jappl.1988.64.3.1030. [DOI] [PubMed] [Google Scholar]
  17. Griswold D. E., Hillegass L., Hill D. E., Sherief H. T., Kopia G. A. Evaluation of the effect of evan's blue and triphenyltetrazolium chloride dyes on myeloperoxidase activity in canine cardiac tissue. J Pharmacol Methods. 1989 Mar;21(1):13–19. doi: 10.1016/0160-5402(89)90018-1. [DOI] [PubMed] [Google Scholar]
  18. Harms B. A., Pahl A. C., Pohlman T. H., Conhaim R. L., Starling J. R., Storm F. K. Effects of interleukin-2 on pulmonary and systemic transvascular fluid filtration. Surgery. 1989 Aug;106(2):339–346. [PubMed] [Google Scholar]
  19. Heslop H. E., Gottlieb D. J., Bianchi A. C., Meager A., Prentice H. G., Mehta A. B., Hoffbrand A. V., Brenner M. K. In vivo induction of gamma interferon and tumor necrosis factor by interleukin-2 infusion following intensive chemotherapy or autologous marrow transplantation. Blood. 1989 Sep;74(4):1374–1380. [PubMed] [Google Scholar]
  20. Jouvin-Marche E., Ninio E., Beaurain G., Tence M., Niaudet P., Benveniste J. Biosynthesis of Paf-acether (platelet-activating factor). VII. Precursors of Paf-acether and acetyl-transferase activity in human leukocytes. J Immunol. 1984 Aug;133(2):892–898. [PubMed] [Google Scholar]
  21. Klausner J. M., Morel N., Paterson I. S., Kobzik L., Valeri C. R., Eberlein T. J., Shepro D., Hechtman H. B. The rapid induction by interleukin-2 of pulmonary microvascular permeability. Ann Surg. 1989 Jan;209(1):119–128. doi: 10.1097/00000658-198901000-00017. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Klausner J. M., Paterson I. S., Morel N. M., Goldman G., Gray A. D., Valeri R., Eberlein T. J., Shepro D., Hechtman H. B. Role of thromboxane in interleukin 2-induced lung injury in sheep. Cancer Res. 1989 Jul 1;49(13):3542–3549. [PubMed] [Google Scholar]
  23. Malavasi F., Tetta C., Funaro A., Bellone G., Ferrero E., Franzone A. C., Dellabona P., Rusci R., Matera L., Camussi G. Fc receptor triggering induces expression of surface activation antigens and release of platelet-activating factor in large granular lymphocytes. Proc Natl Acad Sci U S A. 1986 Apr;83(8):2443–2447. doi: 10.1073/pnas.83.8.2443. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Mojarad M., Hamasaki Y., Said S. I. Platelet-activating factor increases pulmonary microvascular permeability and induces pulmonary edema. A preliminary report. Bull Eur Physiopathol Respir. 1983 May-Jun;19(3):253–256. [PubMed] [Google Scholar]
  25. Nedwin G. E., Svedersky L. P., Bringman T. S., Palladino M. A., Jr, Goeddel D. V. Effect of interleukin 2, interferon-gamma, and mitogens on the production of tumor necrosis factors alpha and beta. J Immunol. 1985 Oct;135(4):2492–2497. [PubMed] [Google Scholar]
  26. Numerof R. P., Aronson F. R., Mier J. W. IL-2 stimulates the production of IL-1 alpha and IL-1 beta by human peripheral blood mononuclear cells. J Immunol. 1988 Dec 15;141(12):4250–4257. [PubMed] [Google Scholar]
  27. Pignol B., Hénane S., Sorlin B., Rola-Pleszczynski M., Mencia-Huerta J. M., Braquet P. Effect of long-term treatment with platelet-activating factor on IL-1 and IL-2 production by rat spleen cells. J Immunol. 1990 Aug 1;145(3):980–984. [PubMed] [Google Scholar]
  28. Rabinovici R., Esser K. M., Lysko P. G., Yue T. L., Griswold D. E., Hillegass L. M., Bugelski P. J., Hallenbeck J. M., Feuerstein G. Priming by platelet-activating factor of endotoxin-induced lung injury and cardiovascular shock. Circ Res. 1991 Jul;69(1):12–25. doi: 10.1161/01.res.69.1.12. [DOI] [PubMed] [Google Scholar]
  29. Rabinovici R., Yue T. L., Farhat M., Smith E. F., 3rd, Esser K. M., Slivjak M., Feuerstein G. Platelet activating factor (PAF) and tumor necrosis factor-alpha (TNF alpha) interactions in endotoxemic shock: studies with BN 50739, a novel PAF antagonist. J Pharmacol Exp Ther. 1990 Oct;255(1):256–263. [PubMed] [Google Scholar]
  30. Rosenberg S. A., Lotze M. T., Muul L. M., Chang A. E., Avis F. P., Leitman S., Linehan W. M., Robertson C. N., Lee R. E., Rubin J. T. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med. 1987 Apr 9;316(15):889–897. doi: 10.1056/NEJM198704093161501. [DOI] [PubMed] [Google Scholar]
  31. Rosenberg S. A., Lotze M. T., Muul L. M., Leitman S., Chang A. E., Ettinghausen S. E., Matory Y. L., Skibber J. M., Shiloni E., Vetto J. T. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med. 1985 Dec 5;313(23):1485–1492. doi: 10.1056/NEJM198512053132327. [DOI] [PubMed] [Google Scholar]
  32. Rosenstein M., Ettinghausen S. E., Rosenberg S. A. Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. J Immunol. 1986 Sep 1;137(5):1735–1742. [PubMed] [Google Scholar]
  33. Ruff M. R., Gifford G. E. Purification and physico-chemical characterization of rabbit tumor necrosis factor. J Immunol. 1980 Oct;125(4):1671–1677. [PubMed] [Google Scholar]
  34. Sakai A., Chang S. W., Voelkel N. F. Importance of vasoconstriction in lipid mediator-induced pulmonary edema. J Appl Physiol (1985) 1989 Jun;66(6):2667–2674. doi: 10.1152/jappl.1989.66.6.2667. [DOI] [PubMed] [Google Scholar]
  35. Shohami E., Rosenthal J., Lavy S. The effect of incomplete cerebral ischemia on prostaglandin levels in rat brain. Stroke. 1982 Jul-Aug;13(4):494–499. doi: 10.1161/01.str.13.4.494. [DOI] [PubMed] [Google Scholar]
  36. Thastrup O., Foder B., Scharff O. The calcium mobilizing tumor promoting agent, thapsigargin elevates the platelet cytoplasmic free calcium concentration to a higher steady state level. A possible mechanism of action for the tumor promotion. Biochem Biophys Res Commun. 1987 Feb 13;142(3):654–660. doi: 10.1016/0006-291x(87)91464-1. [DOI] [PubMed] [Google Scholar]
  37. Thijs L. G., Hack C. E., Strack van Schijndel R. J., Nuijens J. H., Wolbink G. J., Eerenberg-Belmer A. J., Van der Vall H., Wagstaff J. Activation of the complement system during immunotherapy with recombinant IL-2. Relation to the development of side effects. J Immunol. 1990 Mar 15;144(6):2419–2424. [PubMed] [Google Scholar]
  38. Tracey K. J., Fong Y., Hesse D. G., Manogue K. R., Lee A. T., Kuo G. C., Lowry S. F., Cerami A. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature. 1987 Dec 17;330(6149):662–664. doi: 10.1038/330662a0. [DOI] [PubMed] [Google Scholar]
  39. Welbourn R., Goldman G., Kobzik L., Paterson I., Shepro D., Hechtman H. B. Interleukin-2 induces early multisystem organ edema mediated by neutrophils. Ann Surg. 1991 Aug;214(2):181–186. doi: 10.1097/00000658-199108000-00013. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Welbourn R., Goldman G., Kobzik L., Valeri C. R., Shepro D., Hechtman H. B. Involvement of thromboxane and neutrophils in multiple-system organ edema with interleukin-2. Ann Surg. 1990 Dec;212(6):728–733. doi: 10.1097/00000658-199012000-00012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. West W. H., Tauer K. W., Yannelli J. R., Marshall G. D., Orr D. W., Thurman G. B., Oldham R. K. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med. 1987 Apr 9;316(15):898–905. doi: 10.1056/NEJM198704093161502. [DOI] [PubMed] [Google Scholar]
  42. Yue T. L., Gleason M. M., Gu J. L., Lysko P. G., Hallenbeck J., Feuerstein G. Platelet-activating factor (PAF) receptor-mediated calcium mobilization and phosphoinositide turnover in neurohybrid NG108-15 cells: studies with BN50739, a new PAF antagonist. J Pharmacol Exp Ther. 1991 Apr;257(1):374–381. [PubMed] [Google Scholar]
  43. Yue T. L., Gleason M. M., Hallenbeck J., Feuerstein G. Characterization of platelet-activating factor-induced elevation of cytosolic free-calcium level in neurohybrid NCB-20 cells. Neuroscience. 1991;41(1):177–185. doi: 10.1016/0306-4522(91)90208-6. [DOI] [PubMed] [Google Scholar]
  44. Yue T. L., Rabinovici R., Farhat M., Feuerstein G. Pharmacologic profile of BN 50739, a new PAF antagonist in vitro and in vivo. Prostaglandins. 1990 May;39(5):469–480. doi: 10.1016/0090-6980(90)90031-p. [DOI] [PubMed] [Google Scholar]
  45. Zimmerman G. A., McIntyre T. M., Mehra M., Prescott S. M. Endothelial cell-associated platelet-activating factor: a novel mechanism for signaling intercellular adhesion. J Cell Biol. 1990 Feb;110(2):529–540. doi: 10.1083/jcb.110.2.529. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES